Supplementary Table S1: Adverse events occurred during the treatment period in the overall study population (n=136).

Adverse event	**Frequency N (%)**
Anemia	17 (13%)
Asthenia	7 (5%)
Pruritus	4 (3%)
Headache	2 (1%)
Blood pressure elevation	2 (1%)
Jaundice	1 (1%)
Dyspnea	1 (1%)
Syncope	1 (1%)
Tachycardia	1 (1%)
Total Adverse Events	36 (27%)